Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander M Owyang

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
International Immunology|July 31, 2002
c-Rel regulation of the cell cycle in primary mouse B lymphocytesConstance Y Hsia, Shuhua Cheng, Alexander M Owyang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2004
IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12Linda A Lieberman, Fabiola Cardillo, Alexander M Owyang, et al.
Endocrinology|March 25, 2010
XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse modelAlexander M Owyang, Kathrin Maedler, Lisa Gross, et al.
Mabs|November 5, 2010
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseasesAlexander M Owyang, Hassan Issafras, John Corbin, et al.
The Journal of Experimental Medicine|April 12, 2006
Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tractAlexander M Owyang, Colby Zaph, Emma H Wilson, et al.
The Journal of Experimental Medicine|January 4, 2007
IL-25 regulates Th17 function in autoimmune inflammationMelanie A Kleinschek, Alexander M Owyang, Barbara Joyce-Shaikh, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Tuning the Reactivity of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Optimal <i>in Vivo</i> EfficacyVadim Markovtsov, Matthew A J Duncton, Art Bagos, et al.
Blood|August 3, 2013
Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in miceKelley M K Haarberg, Jun Li, Jessica Heinrichs, et al.
The Journal of Biological Chemistry|April 23, 2010
Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activityMarina K Roell, Hassan Issafras, Robert J Bauer, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Immunology|July 31, 2002
c-Rel regulation of the cell cycle in primary mouse B lymphocytesConstance Y Hsia, Shuhua Cheng, Alexander M Owyang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2004
IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12Linda A Lieberman, Fabiola Cardillo, Alexander M Owyang, et al.
Endocrinology|March 25, 2010
XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse modelAlexander M Owyang, Kathrin Maedler, Lisa Gross, et al.
Mabs|November 5, 2010
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseasesAlexander M Owyang, Hassan Issafras, John Corbin, et al.
The Journal of Experimental Medicine|April 12, 2006
Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tractAlexander M Owyang, Colby Zaph, Emma H Wilson, et al.
The Journal of Experimental Medicine|January 4, 2007
IL-25 regulates Th17 function in autoimmune inflammationMelanie A Kleinschek, Alexander M Owyang, Barbara Joyce-Shaikh, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Tuning the Reactivity of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Optimal <i>in Vivo</i> EfficacyVadim Markovtsov, Matthew A J Duncton, Art Bagos, et al.
Blood|August 3, 2013
Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in miceKelley M K Haarberg, Jun Li, Jessica Heinrichs, et al.
The Journal of Biological Chemistry|April 23, 2010
Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activityMarina K Roell, Hassan Issafras, Robert J Bauer, et al.
Pageof 1